Bayer Sees Flat 2026 Profits Amid Roundup Settlement Efforts

Bayer AG forecast profits and sales to be little changed in 2026 as the German agriculture and health company grapples with generic competition for its blockbuster blood thinner and continued uncertainty over its efforts to contain a pesticide litigation in the US.
Source
Bloomberg
Opens original article in a new tab



